Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study

2 references·11 citing·23 second hop

FromToDepth

this work references cited by second hop

References

2011Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer230 cited
2011Accelerated Approval of Oncology Products: The Food and Drug Administration Experience212 cited

Cited by

2020Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017132 cited
2019New drugs: where did we go wrong and what can we do better?130 cited
2017Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015127 cited
2020Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study111 cited
2020Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States96 cited
2020Generating comparative evidence on new drugs and devices after approval87 cited
2020Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe83 cited
2022Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-201983 cited
2017Accelerated Approval and Expensive Drugs — A Challenging Combination81 cited
2020Generating comparative evidence on new drugs and devices before approval79 cited
2015

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

Open innovation in early drug discovery: roadmaps and roadblocks

32 cited